Influenza Pandemic Articles & Analysis
17 news found
Influenza A virus is a genus of virus in the family Orthomyxoviridae and causes influenza in birds and some mammals. ...
These features, and the speed at which Lumen can advance from product concept to GMP-manufactured drug product, offers society a new rapid-response tool for countering future pandemics. The approach is directly translatable to other respiratory viral pathogens with pandemic potential, where interruption of disease transmission will aid in efforts to prevent ...
The funding is provided by BARDA to support the advanced research and development of medical countermeasures (MCM) for chemical, biological, radiological and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases that threaten the U.S. civilian population. ...
This new study will build on Enesi’s successful Biomedical Advanced Research and Development Authority (BARDA) Drive Beyond the Needle collaboration earlier this year, under which the company successfully developed a number of solid-dose formulations of a recombinant H7N9 pandemic influenza vaccine. Under NIAID’s suite of preclinical services, ...
Even prior to the emergence of COVID-19, we have been pursuing a universal immune strategy against type A influenza (the most common and deadly form of seasonal and pandemic flu in both humans and animals), and we have discovered what we believe to be the Achilles’ heel of all type A influenza viruses. It potentially offers broad immunity ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company ...
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global ...
Though the SARS-CoV-2 virus (which causes COVID-19) is straining global resources, its rate of mortality is actually far lower than that seen in cases of exposure to some other influenza viruses. The Spanish flu pandemic affected a staggering number of global citizens, with more than 50 million deaths documented worldwide. Nowadays, access to modern therapeutics ...
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 ...
About CSL CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent seasonal and pandemic influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. ...
In contrast, conventional endotracheal tubes allow pathogenic bacteria to grow on the tube surfaces within hours and form slime-like aggregations of millions of pathogenic cells as a biofilm. In the 1918 influenza pandemic, 95% of influenza patient deaths were caused by secondary bacterial infections. ...
“The year 2018 marks the 100- year anniversary of the Great Influenza Pandemic that killed at least 50 million persons worldwide in a span of 24 weeks. We do not know what might trigger a future deadly pandemic, but the situation with C. auris is worrisome. We are thankful to CDC for providing this valuable testing and we plan to work ...
“The preclinical results we have obtained make us confident in the ability of our IMX313P-based influenza vaccine candidate to improve the effectiveness of current seasonal influenza prevention,” said Alexandre Le Vert, Chief Executive Officer of Imaxio. ...
Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded a funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project: “leveraging On t-cell immune resPonse To Improve influenza VACcines”. The aim of the OPTIVAC project is to improve the ...
Because asthma was the most common underlying health condition among those hospitalized in the United States with 2009 H1N1 influenza infection during the 2009-2010 influenza season, NHLBI and NIAID conducted a collaborative study to establish safe and effective strategies to vaccinate children and adults with mild to severe asthma against the 2009 ...
Because asthma was the most common underlying health condition among those hospitalized in the United States with 2009 H1N1 influenza infection during the 2009-2010 influenza season, NHLBI and NIAID conducted a collaborative study to establish safe and effective strategies to vaccinate children and adults with mild to severe asthma against the 2009 ...
The widespread assumption that pandemic influenza is an exceptionally deadly form of seasonal, or nonpandemic, flu is hard to support, according to a new study in the May issue of the American Journal of Public Health. The study challenges common beliefs about the flu--in particular the Centers for Disease Control and Prevention (CDC) claim that 'the hallmark of ...